{
  "id": 5200874,
  "title": "Avalo Therapeutics CFO Sullivan sells over $1.4m in stock",
  "url": "https://urgent.news/2026/09/02/avalo-therapeutics-cfo-sullivan-sells-over-1-4m-in-stock",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-09-02T23:31:14.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/insider-trading-news/avalo-therapeutics-cfo-sullivan-sells-over-14m-in-stock-93CH-4886877"
  },
  "original_language": "en",
  "account": "Christopher Ryan Sullivan, the CFO of Avalo Therapeutics (NASDAQ: AVTX), disposed of approximately $1.45 million worth of company stock on August 17 and 18, 2026. The sales were made under a Rule 10b5-1 trading plan, which permits company insiders to establish a schedule for buying or selling shares in advance. On August 17, Sullivan sold 37,945 shares at prices ranging from $19.16 to $20.02 each, generating a total of $753,333. The following day, he sold an additional 3,749 shares at prices between $19.70 and $20.02, totaling $697,085. On August 18, he sold a further 31,031 shares at prices from $20.00 to $20.265, amounting to $698,559. In total, Sullivan traded 72,725 shares over the two days. Prior to these sales, Sullivan had acquired 33,907 shares through the exercise of stock options on August 17 and 18, paying $9.88 per share. These acquisitions totaled $335,001. Following the reported transactions, Sullivan now directly owns 39,900 shares of Avalo Therapeutics common stock. Avalo Therapeutics has recently been added to the Russell 2000 and Russell 3000 indexes, placing it among the largest U.S. publicly traded companies. Cantor Fitzgerald maintained an Overweight rating on the company, citing its Phase 2 data for abdakibart in hidradenitis suppurativa. Leerink initiated coverage with an Outperform rating and set a price target of $38.00. Additionally, Ron Philip was appointed to Avalo Therapeutics' board of directors, bringing 30 years of experience in the biopharmaceutical sector. He will serve on the Compensation Committee and the Science, Development, and Commercial Advisory Committee.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Investing.com",
        "title": "Nurix Therapeutics chief legal officer sells over $149k in shares",
        "url": "https://urgent.news/2026/09/03/nurix-therapeutics-chief-legal-officer-sells-over-149k-in-shares",
        "published": "2026-09-03T02:01:05.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}